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FK 506. a potent immunosuppressive macrolide antibi-
otic, has undergone clinical testing at the Presbyte-
rian University and Children's HospitaJ of Pittsburgh since 
January 1989. The initial clinicaJ triaJs were directed at 
liver transplant recipients with refractory rejection 1.2 and 
pursuant to these dramatic and gratifying results FK 506 
was introduced as primary immunosuppression in kidney 
and liver recipients in March 1989.3.4 Since October 1989. 
in a prospective clinicaJ triaJ, 30 patients have undergone 
orthotopic cardiac transplantation with FK 506 and low-
dose steroids as primary immunosuppression. Dramatic 
results were also attained in five patients with cardiac 
rejection refractory to all known conventional treatment 
who underwent rescue therapy with FK 506. 
METHODS 
Patient Group 
Thiny patients were prospectively entered into this study from 
October 1989 to August 1990. Informed consent was obtained 
frdm each patient prior to transplantation for the use of FK 506 
and steroids as the sole immunosuppressive therapy: five patients 
received conventional cyclosporine-based immunosuppression 
during this period. 
In this study group there were 25 males and five females, 22 
were adults and eight children (age range 22 days to 61 years) and 
eight (27%) required mechanical circulatory suppon prior to 
transplantation in the form of the Novacor left ventricular assist 
device (L VAS) (3). intraaonic balloon pump <IABP) (4). and 
extracorporeal membrane oxygenation (ECMOl (I). The etiology 
of cardiomyopathy included idiopathic (II), ischemic (II). con-
genital (5). valvular (2). and hypenrophic (II. In the eight pediatric 
pallents « 18 years). five had complex congenital hean disease. 
Three of the children each had five previous thoracic operations. 
one was on ECMO for 8 days prior to transplantation. and one 
child underwent cardiac transplantation at 22 days of age for 
hypoplastic left hean syndrome (HLHS). Median follow-up of 
these 30 patients was 110 days (range 13-317 days) as of August 
1990. No attempt was made to selectively enroll patients in this 
study based on severity of illness or preoperative status. 
Five patients were treated with FK 506 rescue therapy who had 
cardiac rejection refractory to conventional immunosuppressive 
treatment. There were three children and two adults in this group. 
Two of these patients were referred to our institution from other 
centers. 
FK 506 Therapy 
FK 506 was administered intravenously for 24-72 hours after 
cardiac transplantation at a dose of 0.15/mg/kg/d in two divided 
doses. Oral FK 506 was begun 3&-72 hours after transplantation. 
with a 12-hour overlap with the intravenous drug. upon return of 
gastrointestinal function. The oral maintenance dose of FK 506 
required to attain a level of 1.5-3 ng/mL (12 hour through serum 
ELISA by the technique of Temura)s has ranged from 0.2 to 0.4 
mg/kg/d. Methylprednisolone. 7 mg/kg. was administered intrave-
nously in the operating room and 5 mgtkg postoperatively for 24 
hours in three divided doses. Thereafter patients received 0.15 
mg/kg/d prednisone orally once a day. Prednisone was then 
tapered and discontinued based on rejection history. 
Other Agents 
All patients entered into the FK 506 immunotherapy protocol 
were placed on prophylactic oral trimethoprimlsulfamethoxazole. 
acyclovir. and mycostatin. 
Monitoring lor Rejection 
Posttransplant surveillance on all patients involved weekly trans-
venous endomyocardial biopsies (excluding the neonatal patient) 
during hospitalization and at slowly Increased intervals after 
discharge. Biopsies were graded using hematoxylin and eosin 
staining after light microscopy by a pathologist who was blinded 
to the immunosuppressive protocol of the patient. Biopsy grades 
were defined according to a modified Billingham scale. Rejection 
was defined by the presence of myocyte necrosis in association 
with an interstitial lymphocytic infiltrate (grade 3 or moderate 
rejection) or with hemorrhage (grade 4 or severe rejection I. 
Monitoring for Infection 
All patients were followed by an infectious disease specialist. 
Pretransplant titers for hepatitis B. herpesvirus. Epstein-Barr 
virus (EBV). human immunodeficiency virus <H(V). toxoplasma. 
and cytomegalovirus (CMV) were performed on all donors and 
recipients. The diagnOSIs of infection was made using clinical 
criteria as previously defined by this institution.6 
Complete blood screening was performed daily in the hospital 
and at all follow-up visits. Questionnaires to identify untoward 
side effects of FK 506 were completed on all patients. 
RESULTS 
Survival 
Twenty-six of 30 (86.6%) patients entered into this triaJ are 
alive. The earliest death occurred on the founh postoper-
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Fig 1. Actuarial freedom from rejection. 
ative day secondary to pulmonary hypenension and right 
hean failure. Two other deaths occurred at 30 and 54 days 
from causes unknown: neither of these latter two patients 
had any episode of rejection. One patient died of sudden 
death at horne on an exercise cycle and permission was 
denied for postmonem examination. The other patient 
died of low cardiac output. the etiology of which remains 
unclear despite complete postmonem examination: no 
evidence of cellular or humoral rejection was evident in the 
hean. The founh and latest death occurred in a child at 90 
days secondary to sepsis. This child had preexisting lung 
disease and bronchiectasis and succumbed to pulmonary 
and disseminated cryptococcal infection. Toxoplasmosis 
and cytomegalovirus infections also contributed to this 
patient's demise. In addition. this child had severe 
cachexia. hypoalbuminemia. and hypogammaglobulinemia 
secondary to his cardiac condition. His immunosuppres-
sion consisted of very low-dose FK 506 without steroids 
and no cardiac rejection occurred. No monality has been 
attributed to FK 506 therapy or to acute or refractory 
cardiac rejection. 
Rejection 
At 3 months posttransplant there were 10 episodes of 
rejection in eight patients. Beyond 3 months no new 
episodes of rejection had occurred. Four episodes of 
rejection occurred at 4. 5 and 6 months posttransplant in 
three patients with prior episodes of rejection during the 
first 3 months. The episodes of treated (moderate or 
severe. modified Billingham criteria 3 or 4) rejection at 90 
days in this study were 0.45 per patient (N = 22). The 
actuarial freedom from rejection at 3 months was 60% and 
remained so at 6 and 9 months (Fig I). 
Rejection episodes of moderate severity (Billingham 
criteria 3) were preferentially treated by increased doses of 
FK 506. 4-8 mg/d in the adult patients and 1-4 mg/d in the 
pediatric patients. Moderate or severe rejection (Billing-
ham criteria 3 or 4) was treated either by intravenous 
methylprednisolone. 1 g for 24 or 48 hours. or with a shon 
course oral prednisone taper. 1{)(}-20 mg over 5 days. in 
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those patients in whom FK levels were already in the high 
therapeutic range or in whom azotemia (BUN >50 and 
creatinine >2.0) limited funher manipulation of FK ther-
apy. Only one patient required the addition of other 
immunosuppressive agents: 4 months posttransplant he 
received 5 days of OKT3 (total dose 25 mg) and azathio-
prine was added to this therapy. 
Infection 
Three major infections in two patients were present prior 
to cardiac transplantation. One patient had two pretrans-
plant infections. staphylococcal line sepsis secondary to an 
IABP. and a positive sternal wound culture for Candida at 
the time of Novacor LV AS removal. This same patient 
had pulmonary emboli and infarctions yet remained free of 
infection posttransplant managed on FK 506 as his sole 
immunosuppressive agent. Amphotericin was adminis-
tered for 5 weeks after transplantation. The other patient 
with a pretransplant infection had a klebsiella pneumonia 
during IABP suppon which had been treated for 8 days 
when a donor hean became available. This patient recov-
ered without funher infection. 
Posttransplant there were eight infections in seven of 30 
patients on primary FK 506 therapy. No patient in the 
rescue group had a diagnosed infection. There were four 
(13%) major infections which consisted of two gastrointes-
tinal CMV infections which both responded to ganciciovir. 
one gram-negative pneumonia. and one cryptococcemia 
with CMV and toxoplasmosis which was fatal (see "Sur-
vival"). There were four (13%) minor infections. two 
herpes infections. and two varicella infections in children. 
Freedom from major infection in the primary FK 506 
group at the median follow-up of 110 days is 87%. 
Cardiac Function 
All surviving patients enjoy excellent cardiac function. 
The average left ventricular ejection fraction (L VEF) in 
the group measured by gated nuclear scan and/or echocar-
diography is 70%. The range of L VEF is 58% to 75% at the 
time of longest follow-up. 
Renal Function and Hypertension 
In 20 patients followed for more than 90 days the average 
serum creatinine prior to transplant was 0.9 ng/dL. When 
FK 506 was administered intravenously at a dose of 0.15 
mglkg/d. infused either as bolus therapy twice a day or as 
a continuous 24-hour infusion. there was associated neph-
rotoxicity. Three patients (10%) required dialysis in the 
perioperative period: however. renal function returned 
near baseline within 7-10 days. One of these patients was 
the 22-day-old neonate who had associated renal vein 
thrombosis secondary to venous catheters. One of the two 
adults who required dialysis suffered a cardiac arrest on 
induction to anesthesia and had an IABP insened: these 
events were associated with mild hepatic dysfunction and 
FK 506leve1s greater than 20 ng/mL in the early posttrans-
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plant period. Excluding these three patients who required 
dialysis, peak renal dysfunction occurred at the first post-
operative week and the average serum creatinine was 2.6 
ng/dL (SD = 1.03). This peak renal dysfunction was 
associated with an average FK 506 level of 5.1 ng/mL 
(range 0.8-12 ng/mU. The average serum creatinine at 3 
months follow-up was 1.96 ng/dL (SD = .86) and was 
attained by most patients by the second postoperative 
week. 
Hypertension is rare in patients following cardiac trans-
plantation treated with FK 506 and low-dose steroids. 
Only three of 20 patients (15%) followed for more than 3 
months have required antihypertensive treatment and all 
are well controlled on a single agent. 
Cardiac Rescue Therapy 
Five patients were treated with FK 506 who suffered from 
cardiac rejection refractory to aggressive conventional 
immunotherapy. All of these patients had been treated 
with cyclosporine. azathioprine, and steroids: all had re-
ceived two or more courses of intravenous steroids and 
two or more courses of antilymphocyte therapy (RATG. 
Minnesota ALG, or OKT3) and had persistent rejection. 
In this rescue group three were children. two from our own 
institution and one referred from another center. The three 
children suffered from chronic steroid treatment and had 
marked cushingoid habitus. One adult from our program 
had chronic rejection over 3 years: the other adult had 
unrelenting moderate to severe rejection during the first 
three posttransplant months and was referred to Pittsburgh 
for rescue therapy. 
The rescue patients have tolerated the switch from 
cyclosporine to FK 506 without significant complications. 
Cyclosporine was discontinued 24-48 hours prior to FK 
506 induction. No loading dose of FK 506 was adminis-
tered. The patients were begun on oral FK 506, 0.3 
mg/kg/d, in two divided doses. Azathioprine was discon-
tinued and steroids were given at half the maintenance 
dose. Pending improvement in subsequent biopsies, ste-
roids were tapered and all five patients are on one-quarter 
their previous prednisone dose. All of the children have 
significantly resolved their cushingoid features: one young 
girl lost 12.2 kg. The two patients referred from other 
centers now have normal endomyocardial biopsies. Our 
three patients experienced significant clinical improvement 
and their endomyocardial biopsy readings were the mild 
range (modified Billingham criteria 1-2). 
The two adult FK 506 rescue patients both complained 
of muscle and joint aches and lower limb paresthesias for 
the first few weeks following the switch in therapy. These 
have all resolved. Presumably, these symptoms were 
related to cyclosporine/FK 506 interactions as they have 
not been observed in primary FK 506 patients. Renal 
function has remained normal in all rescue patients. The 
range of follow-up in this group is 90-275 days. 
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Metabolic Studies and Side Effects 
There were eight insulin-dependent diabetics in the 30 
patients on primary FK 506 therapy following cardiac 
transplantation. Three of these eight diabetics were insu-
lin-dependent prior to transplantation. There were five 
new-onset diabetic patients of 27 nondiabetic recipients 
(18.5%). All of the new-onset diabetics were also on 
prednisone (average dose 7 mg/d). 
Continued monitoring of hematologic and coagulation 
indices as well as hepatic function failed to reveal any 
abnormalities in our patients at this follow-up interval. 
Cholesterol and triglycerides have been slightly lower than 
those in cyclosporine-treated patients; however. this is not 
statistically significant. Two patients have borderline ele-
vated uric acid levels. Slightly elevated serum potassium 
levels have also been observed in some patients, indepen-
dent of renal dysfunction. and we have avoided the exog-
enous administration of potassium in this group unless 
specifically indicated (serum K+ < 3.5 mEq/U. 
Side effects have been rare despite routine question-
naires during hospitalization and during outpatient follow-
up. There have been no seizures. cerebrovascular acci-
dents (CV A), or neuropathies secondary to FK 506. One 
patient in the primary therapy group had a thromboem-
bolic occipital CV A with associated hemorrhage and sei-
zure from which he has recovered with little residual 
deficit. There have been occasional reports of extremity 
paresthesia and temperature malsensations usually associ-
ated with elevated FK 506 levels. Muscle aches and mild 
insomnia were also reported rarely. Notably absent in this 
patient group were complaints of gingival hyperplasia, 
tremor. or hirsutism. 
DISCUSSION 
These preliminary results with FK 506 and low-dose 
steroid immunosuppression hold tremendous promise for 
the future, as both primary immunotherapy In cardiac 
transplantation and as an effective agent for rescue therapy 
in refractory cardiac rejection. In a prospective random-
ized study performed at the University of Pittsburgh 
comparing RATG to OKT3 immunoprophylaxis with cy-
cIosporine-based triple-drug therapy the best immunosup-
pressive results were obtained with RATG prophylaxis. 
Using RATG immunoprophylaxis and cycIosporine. aza-
thioprine. and high-dose (20 mg/d) prednisone the actuarial 
freedom from rejection at 90 days posttransplant was 62% 
with 0.42 episode of rejection per patient.7 The actuarial 
freedom from rejection in the FK 506 and low-dose steroid 
immunotherapy group at 90 days posttransplant is 60% 
with 0.45 episode of rejection per patient. We have been 
impressed with the ability of this new agent to attain 
comparable immunosuppression in cardiac transplant re-
cipients to the very best immunosuppressive protocol at 
the University of Pittsburgh during the last decade. This 
level of immunosuppression has been achieved without 
antilymphocyte therapy, without immunoprophylaxis. 
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without azathioprine. and with marked reduction in the 
steroid requirement. Ten of the 30 patients in this study are 
on no steroids at all. including all eight pediatric patients. 
The average steroid dose in the adults is 8.6 mg of 
prednisone per patient. The ability of FK 506 to reverse 
cardiac rejection which has been refractory to aggressive 
treatment with conventional immunotherapeutic tools and 
the relatively low rate of major (13%) and minor (13%) 
infections is further testament to the potency and selectiv-
ity of its immunosuppressive actions. Another added ad-
vantage of FK 506 is the flexibility it introduces to immu-
nosuppressive management. Five of JO episodes of 
rejection which occurred in the first 3 months posttrans-
plant were treated by merely increasing the FK 506 dose. 
All five patients treated for rejection by increasing FK 506 
dose had histological improvement on endomyocardial 
biopsy the following week and only two of the patients 
have had subsequent rejection. The concept of augmenting 
immunosuppression and treating rejection by increasing 
baseline immunotherapy adds a new tool to our armamen-
tarium of antirejection therapy. The biological and immu-
nological basis for this quality of FK 506 is presently under 
intense study at the University of Pittsburgh. 
Despite the excellent tolerance of FK 506 by patients 
and few observed or reported side effects. renal dysfunc-
tion is a price paid when the drug is used as described in 
this report. We believe that systematic overdosing has 
occurred in patients receiving FK 506 intravenously in the 
perioperative period in our attempt to achieve high early 
FK 506 levels. We have changed initial bolus intravenous 
FK 506 therapy to continuous infusion. and now. more 
recently. have lowered the initial intravenous dose to a 
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single 24-hour constant-infusion dose at 0.075 mg/kg. with 
enteral FK 506 begun on the first postoperative day. The 
three patients treated in this manner have not suffered 
from azotemia and oliguria. Further refinements in our 
knowledge regarding FK 506 dosing and therapeutic levels 
together with the diminished incidence of hypertension 
may actually improve the long-term outlook for renal 
function in cardiac transplant recipients. When compared 
to the 40 cardiac transplant recipients transplanted at the 
University of Pittsburgh prior to October 1989. the inci-
dence of hypertension was 70% as opposed to 15% in the 
FK 506 group (P < .001). 
Cardiac function and the quality of life in our small 
patient group have been excellent. Concerns regarding 
vasculitis and neuropathy have not been realized. The 
benefit of steroid sparing and the lack of nonspecific bone 
marrow suppression. antilymphocyte. and antihyperten-
sive therapy hold tremendous promise for the future of 
cardiac transplant recipients. 
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